Compare MasTec Inc (MTZ) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Novo Nordisk A/S — how do they compare? MasTec Inc trades at $350.55 (market cap $26.60B), while Novo Nordisk A/S trades at $49.32 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 8.3× MasTec Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.
| MTZ | NVO | |
|---|---|---|
Market Cap | $26.60B | $220.53B |
Sector | Technology | Health |
52-Week High | $437.51 | $71.70 |
52-Week Low | $172.51 | $35.29 |
Enterprise Value | $29.34B | $239.49B |
Dividend Yield | — | 3.63% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
